title: The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure.
abstract: The Losartan Heart Failure ELITE Study recently found that in patients with symptomatic heart failure and a left ventricular ejection fraction of </=0.40, losartan compared to captopril improved survival with better tolerability. The objective of this study was to perform an economic evaluation of losartan versus captopril based on the results of the Losartan Heart Failure ELITE Study. The Losartan Heart Failure ELITE Study was a multinational, double-blind, randomized 48-week study comparing the safety and efficacy of losartan to captopril in angiotensin-converting enzyme-inhibitor-naive patients >/=65 years with symptomatic heart failure. Data on health care resource utilization were collected as part of the trial. We conducted a cost-effectiveness analysis to estimate the lifetime benefits of treatment and the associated costs. We observed no differences between treatments in the number of hospitalizations, hospital days, and emergency room visits per patient over the trial period. We estimated the total cost of losartan to be USD 54 (95% CI: USD -1,717, USD 1,755) less per patient than captopril over this time frame. We also estimated that over the projected remaining lifetime of the study population, losartan compared to captopril would increase survival by 0.20 years (undiscounted) at an average cost of USD 769 (discounted) more per patient. This cost increase translated into a cost-effectiveness ratio of USD 4,047 per year of life gained for losartan relative to captopril. In patients with symptomatic heart failure, losartan compared to captopril increased survival with better tolerability at a cost well within the range accepted as cost-effective.
authors.affiliation: Merck & Co., Blue Bell, PA 19422, USA.
authors.forename: E J
authors.initials: EJ
authors.lastname: Dasbach
authors.forename: M W
authors.initials: MW
authors.lastname: Rich
authors.forename: R
authors.initials: R
authors.lastname: Segal
authors.forename: W C
authors.initials: WC
authors.lastname: Gerth
authors.forename: G W
authors.initials: GW
authors.lastname: Carides
authors.forename: J R
authors.initials: JR
authors.lastname: Cook
authors.forename: J F
authors.initials: JF
authors.lastname: Murray
authors.forename: D B
authors.initials: DB
authors.lastname: Snavely
authors.forename: B
authors.initials: B
authors.lastname: Pitt
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004358:Drug Therapy / Q000191:economics; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D008017:Life Expectancy; D019808:Losartan / Q000191:economics* / Q000627:therapeutic use; D008297:Male
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D019808:Losartan